These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10918513)

  • 1. Rapamune: a novel macrolide immunosuppressant for transplantation.
    Latta D
    Hum Exp Toxicol; 2000 Apr; 19(4):229. PubMed ID: 10918513
    [No Abstract]   [Full Text] [Related]  

  • 2. Sirolimus. AY 22989, NSC 226080, NSC 606698, rapamycin, Rapamune.
    Drugs R D; 1999 Jan; 1(1):100-7. PubMed ID: 10566001
    [No Abstract]   [Full Text] [Related]  

  • 3. Sirolimus-related toxicity in stem cell transplantation.
    Busca A; Locatelli F; Moscato D; Falda M
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):647-9. PubMed ID: 16041315
    [No Abstract]   [Full Text] [Related]  

  • 4. [Everolimus: immunosuppression with antilymphoproliferative therapy].
    Pascual J
    Nefrologia; 2004; 24(2):112-23. PubMed ID: 15219086
    [No Abstract]   [Full Text] [Related]  

  • 5. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update.
    Cutler C; Antin JH
    Curr Opin Hematol; 2010 Nov; 17(6):500-4. PubMed ID: 20717025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus: a new immunosuppressant.
    Mukherjee T; Shah BV
    J Assoc Physicians India; 2005 Oct; 53():885-90. PubMed ID: 16459533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of immunosuppressive therapy after experimental small bowel transplantation in rats.
    Pech T; Fujishiro J; Finger T; von Websky M; Stoffels B; Wehner S; Abu-Elmagd K; Kalff JC; Schaefer N
    Transpl Immunol; 2011 Sep; 25(2-3):112-8. PubMed ID: 21820512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What role for 15-deoxyspergualin in enhancing engraftment of unrelated, histoincompatible canine marrow grafts and preventing graft-versus-host disease?
    Raff RF; Storb R; Graham T; Deeg HJ; Pepe M; Schaffer R; Sale GE; Schuening F; Appelbaum FR
    Transplantation; 1993 Mar; 55(3):684-8. PubMed ID: 8456496
    [No Abstract]   [Full Text] [Related]  

  • 10. Automated red blood cell exchange for acute drug removal in a patient with sirolimus toxicity.
    Galera P; Martin HC; Welch L; Sulmasy P; Cerny J; Greene M; Vauthrin M; Bailey JA; Weinstein R
    J Clin Apher; 2015 Dec; 30(6):367-70. PubMed ID: 25619898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin suppression of host-versus-graft and graft-versus-host disease in MHC-mismatched rats.
    Fabian MA; Denning SM; Bollinger RR
    Transplant Proc; 1992 Jun; 24(3):1174. PubMed ID: 1604575
    [No Abstract]   [Full Text] [Related]  

  • 12. Sirolimus in pediatric solid organ transplantation.
    Dharnidharka VR
    Pediatr Transplant; 2005 Aug; 9(4):427-9. PubMed ID: 16048592
    [No Abstract]   [Full Text] [Related]  

  • 13. [Contribution to the influence of drugs on acquired tolerance toward homotransplants of skin and organs].
    Oprişiu C; Doroga H; Danciu F; Cojocaru Z
    Stud Cercet Fiziol; 1968; 13(4):287-92. PubMed ID: 4878934
    [No Abstract]   [Full Text] [Related]  

  • 14. Sirolimus: a therapeutic advance for dermatologic disease.
    Peters T; Traboulsi D; Tibbles LA; Mydlarski PR
    Skin Therapy Lett; 2014; 19(4):1-4. PubMed ID: 25188522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model.
    Eggenhofer E; Renner P; Soeder Y; Popp FC; Hoogduijn MJ; Geissler EK; Schlitt HJ; Dahlke MH
    Transpl Immunol; 2011 Sep; 25(2-3):141-7. PubMed ID: 21704160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of RAD and Neoral in inhibition of host-vs.-graft and graft-vs.-host immune responses in rat small-bowel transplantation.
    Johnson S; Qi S; Xu D; Jolicoeur M; Liu D; Barama A; Busque S; Smeesters C; Daloze P; Chen H
    Microsurgery; 2003; 23(5):476-82. PubMed ID: 14558006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The novel immunodepressant rapamune].
    Eksp Klin Farmakol; 2002; 65(2):67-9. PubMed ID: 12109300
    [No Abstract]   [Full Text] [Related]  

  • 18. Prograf produces a molecular environment favoring antifibrosis, an effect reversed by the addition of rapamune.
    Brook NR; Waller JR; Bicknell GR; Nicholson ML
    Transplant Proc; 2005; 37(1):148-9. PubMed ID: 15808577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in immune-based therapies to improve solid organ graft survival.
    Rose SM; Turka L; Kerr L; Rotrosen D
    Adv Intern Med; 2001; 47():293-331. PubMed ID: 11795079
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapamycin effects on immunologic reconstitution.
    Vogelsang GB; Hess AD
    Transplant Proc; 1993 Feb; 25(1 Pt 1):727-8. PubMed ID: 8438459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.